有关华纳 -兰伯特公司生产的抗糖尿病药曲格列酮 ( troglitazone,Rezulin)引发肝衰的争论在美国再度显现出来。某些媒体称 FDA考虑将此药从市场上淘汰掉。不过 FDA目前还不打算这样做 ,但对其有关的肝衰病例要继续监视和分析。曲格列酮自 1 997年上市以来 ,FDA共收到“可能”或 The controversy over Warner-Lambert’s anti-diabetic drug troglitazone (Rezulin) triggering liver failure is once again apparent in the United States. Some media said the FDA considered the drug to be eliminated from the market. However, the FDA is not going to do so at this time, but its related cases of liver failure should continue to be monitored and analyzed. The FDA has received “probably” or “since” the listing of troglitazone since its release in 1997